Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 226 AL 240

Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials

Yoshida K, Seo M, Luo Y, Sahker E, Cipriani A, Leucht S, Iwatsubo T, Efthimiou O, Furukawa TA.

J Alzheimers Dis. 2022;89(4):1143-1157. doi: 10.3233/JAD-220263.

Pharmacological targeting of microglia dynamics in Alzheimer's disease: Preclinical and clinical evidence

Yousefizadeh A, Piccioni G, Saidi A, Triaca V, Mango D, Nisticò R.

Pharmacol Res. 2022 Oct;184:106404. doi: 10.1016/j.phrs.2022.106404. Epub 2022 Aug 18.

Meta-Analysis of the Efficacy and Safety of Olanzapine versus Clozapine when Treating Senile Dementia

Wang Z, Feng Y, Wang Y, Qiu H, Rui Z, Li M, Lv L.

Comput Math Methods Med. 2022 Aug 11;2022:5046761. doi: 10.1155/2022/5046761. eCollection 2022.

Anti-Alzheimer's disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes

Dai R, Sun Y, Su R, Gao H.

Biomed Pharmacother. 2022 Oct;154:113576. doi: 10.1016/j.biopha.2022.113576. Epub 2022 Aug 22.

Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders

Assogna M, Di Lorenzo F, Martorana A, Koch G.

Biomolecules. 2022 Aug 22;12(8):1161. doi: 10.3390/biom12081161.

The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer's Disease

Sun E, Motolani A, Campos L, Lu T.

Int J Mol Sci. 2022 Aug 11;23(16):8972. doi: 10.3390/ijms23168972.

Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach

Morató X, Pytel V, Jofresa S, Ruiz A, Boada M.

Int J Mol Sci. 2022 Aug 18;23(16):9305. doi: 10.3390/ijms23169305.

Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease?

Di Natale G, Sabatino G, Sciacca MFM, Tosto R, Milardi D, Pappalardo G.

Molecules. 2022 Aug 9;27(16):5066. doi: 10.3390/molecules27165066.

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial

Schurad B, Koch C, Schug B, Morte A, Vaqué A, De la Torre R, Iniesta M.

Curr Alzheimer Res. 2022;19(7):541-553. doi: 10.2174/1567205019666220823105059.

Quantitative trait locus (xQTL) approaches identify risk genes and drug targets from human non-coding genomes

Bykova M, Hou Y, Eng C, Cheng F.

Hum Mol Genet. 2022 Oct 20;31(R1):R105-R113. doi: 10.1093/hmg/ddac208.

TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications

Gu Z, Cao H, Zuo C, Huang Y, Miao J, Song Y, Yang Y, Zhu L, Wang F.

Neurobiol Dis. 2022 Oct 15;173:105855. doi: 10.1016/j.nbd.2022.105855. Epub 2022 Aug 27.

γ-Secretase as a drug target for familial Alzheimer's disease: the road less traveled

Wolfe MS.

Future Med Chem. 2022 Oct;14(19):1341-1343. doi: 10.4155/fmc-2022-0178. Epub 2022 Aug 30.

Carthamus tinctorius L.: A natural neuroprotective source for anti-Alzheimer's disease drugs

Liang Y, Wang L.

J Ethnopharmacol. 2022 Nov 15;298:115656. doi: 10.1016/j.jep.2022.115656. Epub 2022 Aug 27.

Neuroinflammation and Oxidative Stress in Alzheimer's Disease; Can Nutraceuticals and Functional Foods Come to the Rescue?

Onaolapo OJ, Olofinnade AT, Ojo FO, Onaolapo AY.

Antiinflamm Antiallergy Agents Med Chem. 2022;21(2):75-89. doi: 10.2174/1871523021666220815151559.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias